- Startseite
- Forschung
- Arbeitsgruppen & Labore
- Labor für molekulare Pathogenese der CLL
- Laboratory of Molecular CLL Pathogenesis
- AG Ambulante Infektiologie
- AG Angewandte Ethik in der translationalen Krebsforschung
- AG Evidenzbasierte Medizin
- AG Intravaskuläre Infektionen und Knocheninfektionen
- AG Klinische Antiinfektiva-Entwicklung und Epidemiologie seltener Infektionen
- AG Klinische Mikrobiomforschung
- AG Kohorten in der Infektionsforschung
- AG Onkologische Bewegungsmedizin
- AG Psychoonkologische Versorgungsforschung
- AG Translationale Tumorgenetik und Immuntherapie
- CLL-Biobank
- Computational Biomedicine & Bioinformatics Group
- Gastrointestinal Cancer Group Cologne
- Krebstherapie und Molekulare Bildgebung
- Labor für antivirale Immunität
- Labor für flüssige Onkogenomik
- Labor für funktionelle Genomik in lymphoiden Neoplasien
- Labor für lymphozytäres Signaling und Onkoproteom
- Labor für Mikromilieu und Therapie Maligner Lymphome
- Labor für molekulare Hämatologie und Onkologie
- Labor für molekulare Immunologie
- Labor für molekulare Pathogenese der CLL
- Labor für präklinische Arzneimittel-Testung
- Labor für translationale Immunmodulation in der Krebstherapie
- Labor für Tumorgenetik und Zellbiologie
- Translational Immune-Oncology
- Translationale Krebsforschungsgruppe
- Translational Research Unit – Infectious Diseases
- Nachwuchsprogramme in der Onkologischen Forschung
- HEnRY
Scientific Focus
Our laboratory is trying to identify novel genes which participate in the development of chronic lymphocytic leukemia. We focus on:
Analysis of the role of the tumor microenvironment for the development and promotion of chronic lymphocytic leukemia (CLL)
CLL is a malignant disease in which the survival of leukemic cells is strongly dependent of continuous stimulation by extracellular factors. We aim to explore this potential "Achilles heel" of CLL using a CLL mouse model and we work to develop novel therapeutic approaches in the future. By using gene knockout mice we analyze the role of cytokines/chemokines and of surface receptors in the development and promotion of CLL.
Target Validation
Here we identify candidate target molecules for the treatment of chronic lymphocytic leukemia (CLL) and other malignant diseases and validate them using animal models. We perform basic research on own molecules as well as on targets defined by others. For every gene, we design the optimal validation strategy and generate the appropriate animal models. This entails the generation of knockout and transgenic mice.
Genetic diagnostic of CLL risk
We work on the identification of small genetic differences between individuals, so called single nucleotide polymorphisms (SNPs), which may explain the great clinical variability of CLL disease. SNPs may help to predict the risk to develop CLL as well as to suffer of progressive disease once CLL is established.
Our long-term goal is to develop novel strategies for the treatment of CLL and other human malignancies. We want to pursue the targets in collaboration with industrial partners and test them in clinical trials.
The Team
Administrative Assistance
Nicole Jörns
Senior Postdocs/Co-PI
Priv.-Doz. Dr. rer. nat. Hinrich Hansen
Dr. rer. nat. Phuong-Hien Nguyen
Medical staff
Daniel Bachurski, Dr. nat. med. cand.
Yannick d‘Hargues
Alexander vom Stein
PhD students
Viktoria Kohlhas, Dr. rer. nat. cand.
Ludmila Lobastova, Dr. rer. nat. cand.
Technical Assistance
H. Bohner
Rebekka Zölzer
Patrick Hölker
Lisa Wessendorf
MD Students
Anton von Lom